Rcp zinplava
Tīmeklis2024. gada 3. sept. · ZINPLAVA (bezlotoxumab) Injection is a sterile, preservative-free, clear to moderately opalescent, colorless to pale yellow solution that requires dilution for intravenous infusion. The product is provided in a 50 mL vial that contains 1000 mg of bezlotoxumab in 40 mL of solution. Each mL of solution contains bezlotoxumab (25 … TīmeklisZINPLAVA(bezlotoxumab)注射液是一种无菌，无防腐剂，清澈至中度地乳光，无色至浅黄色溶液为静脉输注需要稀释。 产品在一个50 mL小瓶内提供其中含1000 mg …
Rcp zinplava
Did you know?
Tīmeklis2024. gada 17. sept. · Z INPLAVA 25 mg/mL solution à diluer pour perfusion (bezlotoxumab) est une nouvelle immunothérapie hospitalière indiquée dans la … TīmeklisZINPLAVA-treated patients compared to placebo-treated patients. In patients with a history of CHF, 12.7% (n=15/118) of ZINPLAVA-treated patients and 4.8% (n=5/104) of placebo-treated patients had the serious adverse reaction of heart failure during the 12-week study period. During the same period, for
TīmeklisZINPLAVA is a human monoclonal antibody that binds to Clostridium difficile toxin B indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving … TīmeklisFormula. C6464H9974N1726O2014S46. Molar mass. 145 565.72 g·mol −1. Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal …
Tīmeklis2024. gada 14. sept. · ZINPLAVA on lääke, jota käytetään yhdessä antibiootin kanssa ehkäisemään Clostridium difficile ( C. difficile) ‑bakteerin aiheuttaman infektion uusiutumista. Valmiste on tarkoitettu 18 vuotta täyttäneille potilaille, joilla C. difficile ‑infektion uusiutumisriski on suuri. Miten ZINPLAVA vaikuttaa Tīmeklis2016. gada 4. dec. · The biggest thing to watch out for with Zinplava is worsening heart failure. But the risk seems to mostly pertain to patients with existing heart failure. In patients with a history of heart failure, 12.7% patients (15/118) in the Zinplava group versus 4.8% (5/104) in the placebo group experienced the major adverse event of …
TīmeklisZINPLAVA concentrated injection is a sterile, preservativefree, clear to moderately opalescent, - colourless to pale yellow liquid that requires dilution for intravenous infusion. Each vial contains bezlotoxumab and the following inactive ingredients: sodium chloride, sodium citrate dihydrate,
TīmeklisThe recommended dose of ZINPLAVA is a single 10-mg/kg dose administered as an IV infusion over 60 minutes. ZINPLAVA must be administered during the course of antibiotic treatment for a CDI episode. ZINPLAVA should be administered using a sterile, nonpyrogenic, low-protein–binding 0.2-micron to 5-micron in-line or add-on filter. equipe hockey angersTīmeklisa CLcr estimated by the Cockcroft-Gault formula. (2.3) b Calculate dosage using Total Body Weight (TBW). For patients with TBW greater than IBW by 25% or more, use adjusted body weight. (2.3) • See Full Prescribing Information for subsequent dosage equipe new zealandTīmeklisZINPLAVA è indicato per la prevenzione della recidiva dell’infezione da Clostridium difficile (CDI) negli adulti ad alto rischio di recidiva di CDI (vedere paragrafi 4.2, 4.4 e 5.1). 4.2 Posologia e modo di somministrazione Posologia ZINPLAVA deve essere somministrato durante il ciclo di terapia antibatterica per CDI (vedere paragrafi 4.4 e ... equipe waveTīmeklis2024. gada 7. sept. · ZINPLAVA a l’AMM en prévention des récidives d’infection à Clostridium difficile (ICD) chez les adultes à haut risque de récidive d’ICD. Son … equipe south townTīmeklisZINPLAVA is a prescription medicine used to help decrease the risk of C-diff from coming back in people 18 years of age or older who are taking an antibiotic for C-diff and who have a high risk of C-diff coming back. C-diff is a bacterial infection that can damage your colon and cause stomach pain and severe diarrhea. When people get finding water leakTīmeklis2024. gada 15. jūl. · Zinplava is a prescription medicine used to treat the symptoms of Clostridium difficile infection (CDI). Zinplava may be used alone or with other medications. Zinplava belongs to a class of drugs called Monoclonal Antibodies. It is not known if Zinplava is safe and effective in children younger than 18 years of age. equipe kansas city chiefsTīmeklisZINPLAVA is a human monoclonal antibody that binds to Clostridium difficile toxin B indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.. ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA … finding water leaks